Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biotech company pioneering novel small molecule therapies for neurodegenerative diseases and rare genetic disorders through its proprietary computational drug discovery platform. This page serves as the definitive source for verified updates on clinical trials, research breakthroughs, and corporate developments.
Investors and researchers will find timely updates on the company’s lead candidate GT-02287 for Parkinson’s disease, along with pipeline progress across lysosomal storage disorders and oncology targets. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations – all essential for understanding GANX’s position in the competitive biopharmaceutical landscape.
Key updates cover three critical areas: clinical trial milestones for brain-penetrant therapies, advancements in AI-driven target identification via the Magellan platform, and strategic collaborations accelerating therapeutic development. Bookmark this page to track how GANX’s focus on allosteric modulation could reshape treatment paradigms.
Gain Therapeutics (Nasdaq: GANX) announced three presentations at Neuroscience 2024, showcasing preclinical data for GT-02287, their lead drug candidate for Parkinson's disease. The event will be held in Chicago from October 5-9, 2024.
Two late-breaking posters will be presented:
- GT-02287's prevention of Tau accumulation in a cellular model
- GT-02287's disease-modifying capacity in both GBA1 and idiopathic Parkinson's disease models
A third presentation will focus on GT-02287's improvement of mitochondrial function and neuroprotective effects in GBA1-Parkinson's disease models. These studies were conducted in collaboration with researchers from Switzerland, supported by an Innosuisse-Swiss Innovation Agency grant.
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company focused on developing next-generation allosteric small molecule therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024.
Gene Mack, Interim CEO and CFO, and Dr. Jonas Hannestad, Chief Medical Officer, will represent Gain Therapeutics at the conference. They will deliver a corporate presentation and engage in one-on-one meetings with potential investors and partners.
This participation provides Gain Therapeutics with an opportunity to showcase its innovative approach to drug discovery and development, potentially attracting investor interest and fostering new collaborations in the biotechnology sector.
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease. The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at all dose levels, with no discontinuations or serious adverse events reported. Importantly, the drug showed presence in the cerebrospinal fluid and achieved peripheral target engagement.
Based on these promising results, Gain plans to initiate a Phase 1b trial in Parkinson's disease patients by Q4 2024, with data expected by mid-2025. The company aims to demonstrate safety, tolerability, and proof of mechanism through relevant biomarkers in this upcoming trial.
Gain Therapeutics (NASDAQ: GANX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Completion of dosing in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial for GT-02287, their lead candidate for Parkinson's disease.
2. Positive results from the Single Ascending Dose (SAD) portion of the Phase 1 trial.
3. Topline results from the MAD study expected in August 2024.
4. Initiation of a Phase 1b study in Parkinson's disease patients anticipated in Q4 2024.
5. Q2 2024 financial results: R&D expenses increased to $4.4 million, G&A expenses remained at $3.7 million, and net loss was $0.42 per share.
6. Cash position of $16.9 million as of June 30, 2024.
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company, announced its participation in the BTIG Virtual Biotechnology Conference on August 5-6, 2024. The company's interim-CEO and CFO, Gene Mack, along with Chief Medical Officer, Jonas Hannestad, will engage in a fireside chat and one-on-one meetings during the event.
Key details:
- Fireside chat scheduled for August 6, 2024, at 4:00pm ET
- Interested parties can arrange meetings through their BTIG representative
- An archived replay of the fireside chat will be available on the company's website
Gain Therapeutics specializes in developing next-generation allosteric small molecule therapies, positioning itself at the forefront of innovative biotechnology research and development.
Gain Therapeutics announced the completion of dosing in the Multiple Ascending Dose (MAD) part of their Phase 1 study for GT-02287, a novel small molecule therapy for Parkinson's Disease. Conducted without any serious adverse events or discontinuations, the study indicates that GT-02287 is well-tolerated. The topline data from this randomized, double-blind, placebo-controlled study is expected in mid-August 2024, with full safety analysis and plasma pharmacokinetics to be presented later. The company aims to initiate trials in Parkinson’s disease patients by Q4 2024. The MAD phase, begun in February 2024, involved 32 healthy volunteers completing 14 days of daily oral doses. The completion of the Single Ascending Dose (SAD) part in April 2024 also reported no serious adverse events. Preclinical data shows GT-02287 effectively restores the function of the enzyme glucocerebrosidase, which is linked to Parkinson’s disease due to GBA1 gene mutations.
Gain Therapeutics (Nasdaq: GANX) has announced a business update conference call scheduled for July 1, 2024, at 8:30am ET, hosted by interim-CEO and current CFO Gene Mack. This call will provide a corporate update and can be accessed via the company's website. A recorded version and transcript will be available on the site within 24 hours post-event.
Gain Therapeutics (NASDAQ: GANX) has announced the appointment of Gene Mack as interim CEO following the departure of Matthias Alder, effective June 25, 2024. Mack will also retain his role as CFO. Khalid Islam, founder and Chairman, will serve as Executive Chairman during the transition. Alder contributed significantly to the company's progress, particularly advancing GT-02287 into clinical development, which recently showed promising preclinical results for improving cognitive performance in GBA1 Parkinson's disease models. The company remains focused on the continued development of GT-02287.
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinical model of GBA1 Parkinson's disease (GBA1-PD). The study demonstrated a reversal of motor function deficits in mice, assessed through nest-building and motor performance tests. The GT-02287 therapy was administered orally and showed promising results in enhancing daily activities reflecting human cognitive performance. The presentation, made on June 27, 2024, aligns with the company’s ongoing Phase 1 clinical study aimed at delivering effective treatments for Parkinson’s disease.
Gain Therapeutics, a clinical-stage biotechnology company, announced that its CFO, Gene Mack, will participate in H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. The event will feature a fireside chat and virtual one-on-one meetings. Attendees can watch the fireside chat starting at 7:00am ET through an on-demand webcast. A replay will be available on Gain Therapeutics' website under the Investors and Media section following the event. Gain Therapeutics is recognized for its work in developing allosteric small molecule therapies.
